TANOVEA® (rabacfosadine for injection) Receives Full FDA Approval as First Treatment for Lymphoma in Dogs; Elanco Acquires Product from VetDC, Inc
By: Colorado BioScience Association Date: 07/19/2021
Elanco Animal Health Incorporated (NYSE: ELAN) announced that the FDA has granted full approval of Tanovea for the treatment of lymphoma in dogs, making this the first conditionally approved new animal drug for dogs that has ever advanced from a conditional to full FDA approval under the FDA’s Minor Use and Minor Species (MUMS) program. Concurrently, Elanco announced the acquisition of the product from VetDC, Inc., which it licensed for further development and commercialization in 2019.
With the full approval, Tanovea becomes one of the most comprehensively studied treatment options for canine lymphoma. The robust scientific evidence of Tanovea’s effectiveness and safety in dogs with lymphoma offers a product the veterinary oncology community can rely on as they guide their patients through their lymphoma treatment journey.
“Tanovea provides veterinarians and pet owners with a novel treatment option for canine lymphoma, of which there are few,” said Aaron Schacht, executive vice president, Innovation, Regulatory and Business Development of Elanco. “Working in collaboration with VetDC allowed us to utilize innovation originally intended for humans to demonstrate efficacy in dogs, and ultimately gain full approval from CVM for Tanovea.”
Find out more in the press release.